New Oncology Launch Study Probes the Investment and Staffing Levels Needed to Successfully Launch a Cancer Drug in the United States

CHAPEL HILL, N.C., June 23, 2017 /PRNewswire/ -- New cancer therapies continue to make their way through the development and approval process in the United States as part of the oncology therapeutic area's resurgence.

But the variety of cancer product types – single indication versus second indication - make it challenging for new product launch leaders to ascertain efficient staffing and investment levels for the launch-related activities of their new oncology products.

Research and consulting leader Best Practices, LLC undertook a primary research project to provide oncology leaders with current staffing and investment benchmarks for launch-related activities and functions for new oncology products. This study will help marketing and brand leaders identify staffing and investment priorities across pre-launch, launch and post-launch activities for oncology products.

According to the new study, market opportunity assessment is a critical parameter affecting overall budget sizes. Peak Year Sales Forecast (PYSF) is the metric that most clearly reflects market opportunity. In turn, market entry budgets correlate with overall opportunity.

For instance, the study found that Peak Year Sales Forecast appears to have the strongest influence on total launch investment for preparing a new oncology product for market entry. For launch year, a new product with a PYSF of less than $750 million had a mean total spend of $8.9 million compared with $54.3 million on average for a product with a PYSF of $750 million to $2 billion.

The new study, "What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace," will inform oncology launch teams with evidence-based benchmarks around investment, staffing and timing requirements needed to successfully launch new oncology drugs in the U.S. market.

For this study, Best Practices, LLC probed oncology product investment levels for 12 companies and 20 U.S. project launches.

Some of the topics addressed in the 148-page study include:

• Total Investment & Staffing Benchmarks Segmented by Peak Year Sales Forecast
• Staffing and Investment Benchmark Analysis for Launch Activities
• Franchise Leverage or Synergy
• U.S. Oncology Market-Entry Trends & Success Factors
• Total Benchmark Class Launch Data & Analysis

This new report benchmarks investment levels at each launch stage as well as budget and staffing allocation across critical medical and commercial activities for various market-entry situations or market-entry archetypes: portfolios featuring multiple molecules which treat single or multiple indications, and portfolios using single molecules to treat individual cancer types.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

SOURCE Best Practices, LLC

Related Links

http://www.best-in-class.com